Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

According to Quest Diagnostics (DGX), this test can differentiate monkeypox viral DNA from other non-variola orthopoxviruses in a specimen, helping to enable a faster final diagnosis.

Quest Diagnostics (DGX) Stock Gains on EUA for Monkeypox Test

First lab-developed test specifically designed to detect Monkeypox virus DNA to receive emergency use authorization during the monkeypox public health emergency SECAUCUS, N.J. , Sept. 7, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the company's lab-developed molecular diagnostic test to aid in the diagnosis of infection with the Monkeypox virus.

FDA Authorizes Quest Diagnostics' Proprietary Monkeypox Test for Emergency Use

Precision medicine innovator uMETHOD now serves Arizona patients in-home; mobile draws in the Greater Phoenix area quadruple in the first month. On-demand remote lab collection supports patients and caregivers across the cognitive decline spectrum, including mild cognitive impairment, mild dementia, and mild Alzheimer's disease.

uMETHOD Taps Getlabs to Deliver In-Home Diagnostics for Patients with Cognitive Decline

Emergent BioSolutions

With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts.

3 Top Monkeypox Stocks to Buy Right Now

With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids

New test panel follows a Quest Diagnostics Health Trends® study with the CDC that revealed less than half of pregnant people are screened for hepatitis C as recommended under guidelines SECAUCUS, N.J. , Aug. 17, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people easily and reliably for hepatitis C (HCV) with other laboratory tests typically ordered during early pregnancy.

Quest Diagnostics Aims to Close Gaps in Maternal Healthcare with New Obstetrics Test Panel that Includes Hepatitis C Screening

NEW YORK--(BUSINESS WIRE)--Paige, a global leader in clinical AI applications for pathology, today announced it will partner with Sonora Quest Laboratories, the local market leader in clinical diagnostics in the state of Arizona, to implement a fully digital pathology workflow at its laboratories. The goal of the digital transformation project is to improve existing diagnostic workflows and accelerate precision diagnoses for patients across Arizona. Under the partnership, Paige will provide Son

Paige Announces Partnership with Sonora Quest Laboratories to Accelerate Precision Diagnostics for Patients Across Arizona

AbbVie

AmerisourceBergen

Bristol-Myers

HCA Healthcare

Labcorp Holdings Inc

McKesson

Merck

Pfizer

Viatris

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

10 defensive stocks that can also provide you with growth and dividends over the long term

SIGA Technologies

A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.

These 3 Companies Are Taking on Monkeypox

IRVING, Texas , Aug. 4, 2022 /PRNewswire/ -- Better healthcare among America's large and growing Hispanic community is receiving an important, new level of support from Quest Diagnostics, the world's leading provider of diagnostic information services, through the launch of a multi-faceted initiative.  "Es Tu Poder," being launched in San Antonio, Houston, Austin, Rio Grande Valley and other communities with large Hispanic populations in the Southwest, is designed to empower better health for Hispanics.

QUEST DIAGNOSTICS BRIDGING ACCESS TO BETTER HEALTH FOR HISPANICS THROUGH ES TU PODER INITIATIVE

SECAUCUS, N.J. , July 27, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2022 Disability Equality Index® (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).

Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Fifth Consecutive Year

Analysis of nearly 23 million lab tests finds only 1 in 3 patients with latent tuberculosis were also tested for chronic hepatitis B, despite similar risk factors in patients Findings heighten caution about use of tuberculosis therapies, which raise risk of liver injury in patients co-infected with chronic hepatitis B virus SECAUCUS, N.J. , July 25, 2022 /PRNewswire/ -- Concurrent testing for chronic hepatitis B (HBV) and tuberculosis (TB) occurs in a minority of patients who test positive for either condition, despite similar risk profiles and, for some, risk of TB therapy-induced liver damage, according to a new Quest Diagnostics Health Trends® study published in the Journal of Public Health Management & Practice.

High Rates of Chronic Hepatitis B and Tuberculosis Co-Infection Observed in Nationally Representative Quest Diagnostics Study

Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2022 Earnings Conference Call July 21, 2022 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Steve Rusckowski - Chairman, President & Chief Executive Officer Jim Davis - Chief Executive Officer-Elect Mark Guinan - Chief Financial Officer Sam Samad - Executive Vice President & Incoming-Chief Financial Officer Conference Call Participants Brian Tanquilut - Jefferies A.J. Rice - Credit Suisse Jack Meehan - Nephron Research Patrick Donnelly - Citi Pito Chickering - Deutsche Bank Ricky Goldwasser - Morgan Stanley Rachel Vatnsdal - JPMorgan Operator Good morning.

Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2022 Results - Earnings Call Transcript

Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.

Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates

Quest Diagnostics Inc. DGX, -1.33% said Thursday its second-quarter net income fell to $234 million, or $1.96 a share from $631 million, or $4.96 a share in the year-ago quarter. Adjusted profit in the latest quarter totaled $2.36 a share.

Quest Diagnostics profit drops but testing firm raises 2022 view

Second quarter revenues of $2.45 billion, down 3.8% from 2021 Second quarter reported diluted earnings per share ("EPS") of $1.96, down 60.5% from 2021; and adjusted diluted EPS of $2.36, down 25.8% from 2021 Second quarter base business revenues of $2.10 billion, up 2.9% from 2021 Full year 2022 reported diluted EPS now expected to be between $8.24 and $8.64; and adjusted diluted EPS expected to be between $9.55 and $9.95 SECAUCUS, N.J. , July 21, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2022.

Quest Diagnostics Reports Second Quarter 2022 Financial Results; Raises Guidance for Full Year 2022

Rite Aid

PHILADELPHIA & SECAUCUS, N.J.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) today announced it is collaborating with Quest Diagnostics (NYSE: DGX) to provide access to quality, COVID-19 molecular testing (polymerase chain reaction or similar nucleic acid amplification test) to help Rite Aid customers detect and prevent the spread of COVID-19. Quest is the world's leading provider of diagnostic information services and a national leader in COVID-19 testing. The company has performed more than 69 millio

Rite Aid and Quest Diagnostics Expand Access to COVID-19 PCR Testing Nationwide

F.N.B. Corp.

Halliburton

NextEra Energy

Schlumberger

Five dividend-paying companies will report second-quarter 2022 earnings results next week. These are: HAL, FNB, DGX, SLB and NEP.

5 Dividend-Paying Stocks to Buy Ahead of Earnings Next Week

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.

Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?

Quest Diagnostics Inc. DGX, -1.38% said Wednesday that it developed a monkeypox test that it plans to launch in August. The PCR test, which is administered by a physician, can detect monkeypox and also differentiate that virus from other non-variola orthopoxviruses, the company said.

Quest Diagnostics to launch monkeypox test in August

Company to be able to perform approximately 30,000 tests a week by the end of July, supplementing public health response Physicians can order the novel Quest Diagnostics lab test beginning today and the CDC orthopoxvirus test the first half of August SECAUCUS, N.J. , July 13, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the nationwide availability* of the company's lab-developed molecular diagnostic test to aid in the diagnosis of infection with the monkeypox virus, with plans to launch the CDC's orthopoxvirus test in the first half of August.

Quest Diagnostics Launches Monkeypox Virus Testing

Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.

Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal

SECAUCUS, N.J. , July 11, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today released its 2021 Corporate Responsibility Report.

News for Quest Diagnostics Stock (DGX)